Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (IMNN) generates frequent news as a clinical-stage biotechnology company advancing DNA-mediated immunotherapies and DNA vaccine technologies. Most coverage centers on its lead program, IMNN-001, a TheraPlas-based IL-12 DNA immunotherapy in Phase 3 development for newly diagnosed advanced ovarian cancer, and on its PlaCCine DNA vaccine platform, including the IMNN-101 COVID-19 booster candidate.
Investors following IMNN news can expect regular updates on clinical trial progress, such as enrollment milestones, translational data and survival outcomes from the OVATION 2 Phase 2 study and the pivotal OVATION 3 Phase 3 trial. Company releases describe how IMNN-001 is being evaluated in combination with standard neoadjuvant and adjuvant chemotherapy, and how biomarker data show shifts in the tumor microenvironment toward more active anti-tumor immunity.
Another major news theme is scientific and medical conference activity. Imunon frequently announces posters and presentations at meetings such as the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the International Gynecologic Cancer Society and specialized ovarian cancer conferences. These items often include new translational data on immune cell changes, cytokine profiles and clinical outcomes associated with IMNN-001.
Imunon also issues news on corporate and financial developments, including quarterly financial results, R&D Day events, capital markets transactions like registered direct offerings and at-the-market equity programs, and Nasdaq listing-related updates. For the PlaCCine platform, news items highlight proof-of-concept data for IMNN-101 and presentations at international vaccine conferences.
For readers tracking IMNN, this news feed provides a consolidated view of clinical milestones, scientific recognition, financing activities and regulatory communications that shape the company’s development trajectory in oncology and DNA vaccine research.
IMUNON (NASDAQ: IMNN) has appointed Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer, effective February 18, 2025. Dr. Faller brings over 30 years of industry, academic, and laboratory experience, specializing in oncology and immunology. He will lead the company's clinical strategy, including advancing IMNN-001 for newly diagnosed advanced ovarian cancer into a Phase 3 pivotal trial in Q1 2025.
Dr. Faller previously served as Chief Medical Officer at Skyhawk Therapeutics and Oryzon Genomics, and held executive positions at Takeda. The Phase 2 OVATION 2 Study has shown promising results, demonstrating clinically meaningful improvements in overall survival and progression-free survival in women treated with IL-12 immunotherapy plus chemotherapy.
As part of his appointment, Dr. Faller will receive inducement stock options to purchase 100,000 shares of common stock, vesting over four years.
IMUNON (NASDAQ: IMNN) announced a successful Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the FDA regarding IMNN-001, their DNA-mediated immunotherapy for advanced ovarian cancer. The FDA aligned with IMUNON's manufacturing strategy and requirements for their upcoming 500-patient Phase 3 pivotal trial, scheduled to begin in Q1 2025.
Key outcomes include FDA's acceptance of the company's potency assay measuring interferon-gamma (IFN-γ) for both Phase 3 and commercial use, and agreement on the strategy to establish comparability between IMUNON's in-house manufacturing and previous CDMO-produced components. The company's Huntsville, Alabama facility will handle the manufacturing process, ensuring cost-efficient production for both clinical trials and potential commercialization.
IMUNON (NASDAQ: IMNN) reported improved overall survival (OS) data from its Phase 2 OVATION 2 Study of IMNN-001 for advanced ovarian cancer treatment. After seven additional months of monitoring, the hazard ratio improved from 0.74 to 0.69, with median OS increasing from 11.1 to 13 months in the IMNN-001 plus standard-of-care (SoC) treatment group compared to SoC alone.
The study, involving 112 newly diagnosed advanced ovarian cancer patients, showed that over one-third of participants survived beyond 36 months, with 62% from the IMNN-001 treatment arm. The treatment maintained its favorable safety profile with no serious immune-related adverse events. IMUNON plans to initiate a Phase 3 pivotal trial in Q1 2025.
IMUNON (NASDAQ: IMNN) announced successful results from its End-of-Phase 2 meeting with the FDA for IMNN-001, its DNA-mediated immunotherapy for advanced ovarian cancer. The FDA supported the company's proposed Phase 3 trial strategy, including trial design, patient population, and endpoints. The 500-patient Phase 3 trial is scheduled to begin in Q1 2025. The company's Phase 2 OVATION 2 Study showed approximately one-year (35%) improvement in overall survival when IMNN-001 was combined with standard chemotherapy compared to chemotherapy alone. The treatment demonstrated good tolerability with no serious immune-related adverse events.
IMUNON announced positive Phase 2 OVATION 2 trial results for IMNN-001 in advanced ovarian cancer. The study of 112 patients showed that IMNN-001 plus standard chemotherapy improved overall survival by 35% (40.5 vs 29.4 months) and progression-free survival by 25% (14.9 vs 11.9 months) compared to chemotherapy alone. The treatment demonstrated better surgical outcomes with a 64.6% response rate versus 52.1% for standard care. IMNN-001 was well-tolerated with no serious immune-related adverse events. The company plans to initiate a Phase 3 pivotal trial in Q1 2025 following FDA discussions.
IMUNON reported Q3 2024 financial results and provided updates on its clinical developments. The company highlighted compelling topline results from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer, showing an 11.1-month overall survival improvement compared to standard care. The company plans to begin a 500-patient pivotal Phase 3 study in Q1 2025. Financial results showed $10.3 million in cash and investments as of September 30, 2024, with Q3 net loss of $4.9 million ($0.34 per share). Research and development expenses increased to $3.3 million from $2.0 million in Q3 2023.
IMUNON (NASDAQ: IMNN) has scheduled its Third Quarter 2024 Financial Results conference call for Thursday, November 7, 2024, at 11:00 a.m. ET. The company will discuss Q3 2024 financial performance and provide updates on two key programs: IMNN-001, a DNA-based IL-12 immunotherapy for first-line ovarian cancer treatment, and PlaCCine, their DNA plasmid technology for next-generation vaccine development. The call will be accessible via phone and webcast, with replay available until November 21, 2024.
IMUNON announced the acceptance of late-breaking data presentation from Phase 2 OVATION 2 Study of IMNN-001 at SITC's 39th Annual Meeting. The study showed an 11.1-month increase in median overall survival among patients treated with IMNN-001 compared to standard care, representing a 35% improvement in survival. The company will hold an in-person End-of-Phase 2 meeting with the FDA to discuss the design of a Phase 3 pivotal study, expected to begin in Q1 2025. IMNN-001 is a DNA-mediated immunotherapy using TheraPlas® platform technology, designed to produce and secrete IL-12 protein for strong anti-cancer immunity.
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy, has announced the approval of inducement stock options by its Compensation Committee. The grants include:
1. Options to purchase 60,000 shares of common stock for one individual hired in Q4 2024.
2. Options to purchase 50,000 shares of common stock for Susan Eylward, hired as General Counsel and Secretary effective October 7, 2024.
These grants, made on October 7, 2024, comply with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary and the remainder vesting annually until fully vested on the fourth anniversary, subject to continued employment.
IMUNON (NASDAQ: IMNN) announced its first Ovarian Cancer R&D Day on September 18, 2024, in New York City. The event will focus on IMNN-001, their investigational DNA-mediated immunotherapy for advanced ovarian cancer. Key presentations will cover:
1. Positive topline data from the Phase 2 OVATION 2 Study, showing an 11.1-month increase in median overall survival.
2. Insights from clinical investigators, immunology experts, and biostatisticians.
3. The role of IL-12 in cancer treatment.
4. Ongoing Phase 1/2 study of IMNN-001 with bevacizumab.
5. Plans for a Phase 3 registration study.
The event aims to highlight IMNN-001's potential to change the treatment paradigm for newly diagnosed ovarian cancer patients.